Pre-made Edrecolomab benchmark antibody ( Whole mAb, anti-EPCAM therapeutic antibody, Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Edrecolomab biosimilar, Whole mAb, Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Edrecolomab (MAb17-1A, trade name Panorex) is a mouse-derived monoclonal antibody targeting the cell-surface glycoprotein EpCAM (17-1A), which is expressed on epithelial tissues and on various carcinomas.
| Products Name (INN Index) | Pre-Made Edrecolomab biosimilar, Whole mAb, Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody |
|---|---|
| INN Name | Edrecolomab |
| Target | EPCAM |
| Format | Whole mAb |
| Derivation | Mouse |
| Species Reactivity | Human |
| CH1 Isotype | IgG2a |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved (w) |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 1995 |
| Year Recommended | 1996 |
| Companies | Ajinomoto,Centocor Inc |
| Conditions Approved | Colorectal cancer |
| Conditions Active | NA |
| Conditions Discontinued | Adenocarcinoma,Pancreatic cancer |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | EPCAM |
| Package |
